Paratek Pharmaceuticals, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    €128.61M +24.7% -€54.22M +7.6% -42.2% +0.067 pp -€56.38M +38.0% -43.8% -0.042 pp
    €103.17M +177.9% -€50.40M -49.2% -48.8% +2.2 pp -€40.86M -53.5% -39.6% +2.0 pp
    €37.12M +163.0% -€99.16M -9.7% -267.2% +5.1 pp -€87.89M -23.0% -236.8% +5.7 pp
    €14.11M -3.3% -€109.85M +14.6% -778.5% -1.2 pp -€114.13M +65.0% -808.8% -3.3 pp
    €14.60M +35.7% -€95.83M +26.1% -656.4% +0.50 pp -€69.19M +4.7% -473.9% +1.4 pp
    €10.76M +43,403.4% -€75.97M -20.2% -706.0% +3.8K pp -€66.07M -17.1% -614.0% +3.2K pp
    €24.74K +∞% -€95.22M +57.5% -384,951.7% -3.8K pp -€79.67M +73.5% -322,096.6% -3.2K pp
    €0.00 -100.0% -€60.44M +297.3% N/A -€45.91M +190.4% N/A
    €3.70M +148.5% -€15.21M -35.0% -410.8% +12 pp -€15.81M +24.9% -426.8% +4.2 pp
    €1.49M -84.2% -€23.41M +128.4% -1,571.0% -15 pp -€12.66M -2.1% -849.3% -7.1 pp
    €9.40M -44.0% -€10.25M +209.7% -109.0% -0.89 pp -€12.93M +168.4% -137.5% -1.1 pp
    €16.80M +57.6% -€3.31M -58.3% -19.7% +0.55 pp -€4.82M -71.0% -28.7% +1.3 pp
    €10.66M +140.0% -€7.94M -57.3% -74.4% +3.4 pp -€16.62M -1,797.1% -155.9% -1.8 pp
    €4.44M -91.4% -€18.59M -162.6% -418.6% -4.8 pp €979.19K -110.5% 22.0% +0.40 pp
    €51.71M +263.4% €29.70M -207.0% 57.4% +2.5 pp -€9.30M -157.8% -18.0% -1.3 pp
    €14.23M +4,396.8% -€27.75M +9.8% -195.0% +78 pp €16.07M -172.8% 113.0% +71 pp
    €316.44K +562.5% -€25.27M +24.5% -7,986.0% +350 pp -€22.08M +21.4% -6,978.7% +310 pp
    €47.77K -95.0% -€20.30M +32.6% -42,508.9% -410 pp -€18.19M +25.8% -38,080.4% -370 pp
    €955.31K -€15.31M -1,602.9% -€14.46M -1,513.6%

    Notifications